title: Off-licence use of once-daily maraviroc in children and adolescents with perinatally acquired HIV-1 infection.
authors.affiliation: Visiting Nuffield Scholar, London, W2 1NY.
authors.forename: T
authors.initials: T
authors.lastname: Fraser-Taliente
authors.affiliation: Imperial College Healthcare NHS Trust, London, W2 1NY.
authors.forename: N E
authors.initials: NE
authors.lastname: Mackie
authors.affiliation: Imperial College, London, W2 1NY.
authors.forename: S
authors.initials: S
authors.lastname: Kaye
authors.affiliation: Imperial College Healthcare NHS Trust, London, W2 1NY.
authors.forename: M
authors.initials: M
authors.lastname: Nyirenda
authors.affiliation: Imperial College Healthcare NHS Trust, London, W2 1NY.
authors.forename: C
authors.initials: C
authors.lastname: Foster
mesh_terms: D000293:Adolescent; D065100:CCR5 Receptor Antagonists / Q000008:administration & dosage* / Q000009:adverse effects; D002648:Child; D003510:Cyclohexanes / Q000008:administration & dosage* / Q000009:adverse effects; D005260:Female; D015658:HIV Infections / Q000188:drug therapy*; D006801:Humans; D008297:Male; D000077592:Maraviroc; D056687:Off-Label Use; D012189:Retrospective Studies; D016896:Treatment Outcome; D014230:Triazoles / Q000008:administration & dosage* / Q000009:adverse effects
chemical_list: D065100:CCR5 Receptor Antagonists; D003510:Cyclohexanes; D014230:Triazoles; D000077592:Maraviroc